washington  reuters    a top u s  lawmaker accused the food and drug administration on friday of failing to hand over documents that would show whether its criminal office is fulfilling the critical mission of protecting public health   the fda s long overdue response leaves key questions unanswered about the performance and effectiveness of the fda s office of criminal investigations   house of representatives energy and commerce committee chairman greg walden told reuters in a statement  an fda spokeswoman did not have an immediate comment  walden s comments come about four months after the congressional panel launched an examination into the criminal office and how it was managing cases involving food  drugs and devices  the review came after reuters reported that fda agents were concerned that managers  including former oci director george karavetsos  were forcing them to pursue often toothless cases involving mislabeled foreign imported injectable drugs  at the expense of cases with more potential to protect the public health  the agents said they had become the  botox police  and were spending hours chasing down doctors who purchased authentic versions of allergan s popular anti wrinkle drug that were labeled for use in other countries  those concerns came at a time when the office was seeing more than half its opened cases ultimately get closed without action  reuters found  reuters also reported on how the fda permitted karavetsos to relocate back to florida in mid  and run the oci from its miami office  even after the fda had already paid more than    to move him to maryland in   the fda did not meet the committee s october deadline to provide written answers to questions until jan    the next day  karavetsos departed to work for dla piper where he will represent drug and device industry clients  in its letter reviewed by reuters  the fda listed its investigative priorities and said that traditional metrics used to gauge success  such as arrests and convictions  cannot capture the impact of its public health mission  it also provided annual data on arrests  convictions  and the number of opened cases  however  it omitted preliminary stage investigative numbers from the total number of cases opened each year  which makes the conviction rate appear higher  according to a side by side comparison  walden said the fda did not provide a performance plan  among other things  he also complained of redactions on a separate record  which according to a committee aide contained salary and compensation information for karavetsos  